HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial

Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality following organ transplantation. Cell-mediated immunity plays a crucial role in controlling CMV replication after transplantation. Immune monitoring involves the use of immune biomarkers to dynamically estimate the risk of CMV replication. This approach allows for the individualization of preventive and therapeutic strategies, improving patient outcomes. The HORUS-COPE trial is designed to assess the effect of immune modulation on CMV replication kinetics and to explore the performance of a selected immune signature during antiviral therapy for CMV infection to stratify patients based on their risk of not responding to immune modulation.

NCT Number	NCT07570433
Lead Sponsor	Oriol Manuel Collaborators: Centre Hospitalier Universitaire Bordeaux, Centre Hospitalier Universitaire de Toulouse, FRANCE, Hospital Vall d'Hebron
Conditions	CMV Infection
Enrollment	100 participants
Start Date	2026-04
Primary Completion	2028-01 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2026-05-06